Commencement of production activity
Commenced Commercial activities and converted to public limited as ViNS Bioproducts Ltd.
Obtain WHO GMP Certification
Recognition of the successful performance the company has received the award of PARISRAMIK VIJETHA from the State Financial Corporation for best credit rating during 2003-04.
Develop & manufacture African antisera with 10 African snake species both in liquid and lyophilized form
Commercial operations commence in New GMP facility at Thimmapur.
Products registered with all the SAARC Nations and Seven African Countries.
Recognition of In-house R&D Unit by DSIR, New Delhi.
Launched MENAVEN (or) BIOSNAKE (Snake Venom Antitoxin) in MENA Region.
launched MENASCORP (anti scorpion) for Middle East and North Africa (MENA) region.
Launched GANGREVIN (Mixed Gangrene Antitoxin).
The DGFT, Delhi has given us the One Star Export House status.
Launched Echis Monovalent and Anti Tetanus Serum.
PICs GMP received and approved by PICs country.
Vinsbio supplies to over 110 countries spread across Asia, Africa, Middle East, Europe, Australia and North and South America.
The University of Hyderabad (UoH) and CSIR-Centre for Cellular & Molecular Biology (CCMB) in collaboration with Vinsbio and touted to be the country’s first antidote and a cure against SARS-CoV-2 virus.
Vinsbio has successful completion of phase 2 clinical trials of ‘VINCOV-19’,
Over 25 years, our commitment to producing antisera products has become a cornerstone of scientific excellence and healthcare.
